Catalent, a Somerset-based provider of technologies and solutions for health products, announced Tuesday it has invested $14 million to expand integrated turnkey softgel capabilities at its 360,000-square-foot facility in Eberbach, Germany.
The expansion, which is slated for completion by mid-2020, includes two new softgel encapsulation lines for Catalent’s Vegicaps technology, new printing technology, an inspection system, expansion of the facility’s softgel coating capabilities and the addition of more packaging capacity.
“The Eberbach facility is our biggest softgel development and manufacturing facility in Europe with a capacity of more than 10 billion softgel capsules per year,” Raoul Bernhardt, general manager of the Eberbach facility, said. “This investment reflects the importance of the site and will enable us to better serve our customers with increased volumes and turnkey services.”
In addition to the capital investment, Catalent said it plans increase its workforce at the facility by more than 10% across operations, quality control and related supporting functions.